Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Promethazine · Phenergan

Small molecule · Antagonist of histamine H1 receptor (HRH1) · developed by Delcor Asset

Approved FDA, Mar 1951
1 Registered trials

What is Promethazine?

Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors and binds muscarinic receptors, producing antihistaminic, anticholinergic and antiemetic effects. It has been studied for nausea and vomiting in patients with hepatic impairment, including hepatic coma in hepatitis C.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Phenergan
Drug type
Small molecule
Targets
histamine H1 receptor (HRH1), muscarinic receptors (secondary target)
Mechanism
Antagonist of histamine H1 receptor (HRH1)
Pathways
histamine signaling, cholinergic signaling
Therapy area
Gastroenterology
Developer
Delcor Asset Corp
In trials of
INDV
FDA status
Approved as Phenergan (March 29, 1951), NDA007935
UNII
YS4J699MRE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01846455 Phase 4 Hepatic Failure Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis C Infection With Hepatic ComaHepatic FailureHepatic Impairment

Other drugs acting on HRH1

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.